{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:34:21Z","timestamp":1780331661681,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12325-024-02991-x","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T04:02:03Z","timestamp":1729051323000},"page":"4537-4556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Phase\u00a03, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct05029622","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feihong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"issue":"2","key":"2991_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12020-021-02630-3","volume":"72","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yu T, Li X, et al. Prevalence of precocious puberty among Chinese children: a school population-based study. Endocrine. 2021;72(2):573\u201381.","journal-title":"Endocrine"},{"key":"2991_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.910119","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ni J, Zhang L, et al. The prevalence of precocious puberty among children in Qufu City, Shandong Province, China, a population-based study. Front Endocrinol. 2022;13:910119.","journal-title":"Front Endocrinol"},{"issue":"6","key":"2991_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1542\/peds.2005-0012","volume":"116","author":"G Teilmann","year":"2005","unstructured":"Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics. 2005;116(6):1323\u20138.","journal-title":"Pediatrics"},{"issue":"4","key":"2991_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/cen.14475","volume":"95","author":"L Maione","year":"2021","unstructured":"Maione L, Bouvattier C, Kaiser UB. Central precocious puberty: recent advances in understanding the aetiology and in the clinical approach. Clin Endocrinol (Oxf). 2021;95(4):542\u201355.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2991_CR5","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.pedn.2022.01.002","volume":"64","author":"M L\u00f3pez-Miralles","year":"2022","unstructured":"L\u00f3pez-Miralles M, Lacomba-Trejo L, Valero-Moreno S, Benavides G, P\u00e9rez-Mar\u00edn M. Psychological aspects of pre-adolescents or adolescents with precocious puberty: a systematic review. J Pediatr Nurs. 2022;64:e61\u20138.","journal-title":"J Pediatr Nurs"},{"issue":"5","key":"2991_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/js.2019-00036","volume":"3","author":"EA Eugster","year":"2019","unstructured":"Eugster EA. Treatment of central precocious puberty. J Endocr Soc. 2019;3(5):965\u201372.","journal-title":"J Endocr Soc"},{"issue":"10","key":"2991_CR7","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1007\/s00431-021-04022-1","volume":"180","author":"AV Cheuiche","year":"2021","unstructured":"Cheuiche AV, da Silveira LG, de Paula LCP, Lucena IRS, Silveiro SP. Diagnosis and management of precocious sexual maturation: an updated review. Eur J Pediatr. 2021;180(10):3073\u201387.","journal-title":"Eur J Pediatr"},{"key":"2991_CR8","unstructured":"Ipsen Limited. Patient information leaflet; Diphereline\u00ae Triptorelin Acetate for Injection Leaflet. 2022."},{"key":"2991_CR9","unstructured":"Ipsen Limited. Patient informatin leaflet; Diphereline\u00ae Triptorelin Pamoate for Injection Leaflet. 2022."},{"key":"2991_CR10","unstructured":"Takeda. Patient information leaflet; Leuprorelin Acetate Microspheres (3.75MG [CN]) for Injection Leaflet. 2021."},{"key":"2991_CR11","unstructured":"Takeda. Patient information leaflet; Leuprorelin Acetate Microspheres (11.25MG [CN]) for Injection Leaflet. 2021."},{"key":"2991_CR12","unstructured":"Ipsen Limited. Summary of product characteristics, Decapeptyl SR 22.5mg (triptorelin pamoate). Electronic Medicines Compendium, 2024. https:\/\/www.medicines.org.uk\/emc\/product\/5906\/smpc\/print. Accessed May\u00a02024."},{"key":"2991_CR13","unstructured":"European Medicines Agency (EMA), List of nationally authorised medicinal products, Active substance(s): triptorelin. https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/triptorelin-list-nationally-authorised-medicinal-products-psusa00003048202203_en.pdf (Accessed May\u00a02024)."},{"issue":"11","key":"2991_CR14","first-page":"1241","volume":"29","author":"K Klein","year":"2016","unstructured":"Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29(11):1241\u20138.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2991_CR15","doi-asserted-by":"publisher","first-page":"1134977","DOI":"10.3389\/fendo.2023.1134977","volume":"14","author":"E Yoo","year":"2023","unstructured":"Yoo E, Kim S, Jung HL, et al. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty. Front Endocrinol (Lausanne). 2023;14:1134977.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2991_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1530\/eje.1.02056","volume":"154","author":"JC Carel","year":"2006","unstructured":"Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N. Three-month sustained-release triptorelin (11.25\u00a0mg) in the treatment of central precocious puberty. Eur J Endocrinol. 2006;154(1):119\u201324.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2991_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000448840","volume":"86","author":"D Zenaty","year":"2016","unstructured":"Zenaty D, Blumberg J, Liyanage N, et al. A 6-month trial of the efficacy and safety of triptorelin pamoate (11.25\u00a0mg) every 3\u00a0months in children with precocious puberty: a retrospective comparison with triptorelin acetate. Horm Res Paediatr. 2016;86(3):188\u201395.","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"2991_CR18","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1007\/s12325-023-02617-8","volume":"40","author":"X Luo","year":"2023","unstructured":"Luo X, Zhang C, Yang Y, et al. Efficacy and safety of triptorelin 3-month formulation in Chinese children with central precocious puberty: a phase\u00a03, open-label, single-arm study. Adv Ther. 2023;40(10):4574\u201388.","journal-title":"Adv Ther"},{"issue":"8","key":"2991_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1515\/JPEM.2006.19.8.963","volume":"19","author":"A Mart\u00ednez-Aguayo","year":"2006","unstructured":"Mart\u00ednez-Aguayo A, Hern\u00e1ndez MI, Beas F, et al. Treatment of central precocious puberty with triptorelin 11.25\u00a0mg depot formulation. J Pediatr Endocrinol Metab. 2006;19(8):963\u201370.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"34","key":"2991_CR20","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e219","volume":"36","author":"LY Chung","year":"2021","unstructured":"Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH. Efficacy of triptorelin 3-month depot compared to 1-month depot for the treatment of Korean girls with central precocious puberty in single tertiary center. J Korean Med Sci. 2021;36(34):e219.","journal-title":"J Korean Med Sci"},{"issue":"4","key":"2991_CR21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000456545","volume":"87","author":"A Durand","year":"2017","unstructured":"Durand A, Tauber M, Patel B, Dutailly P. Meta-analysis of paediatric patients with central precocious puberty treated with intramuscular triptorelin 11.25\u00a0mg 3-month prolonged-release formulation. Horm Res Paediatr. 2017;87(4):224\u201332.","journal-title":"Horm Res Paediatr"},{"key":"2991_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882840","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen L, Su B, Zhang Y, et al. Association between height growth patterns in puberty and stature in late adolescence: a longitudinal analysis in Chinese children and adolescents from 2006 to 2016. Front Endocrinol (Lausanne). 2022;13:882840.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2991_CR23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1159\/000535132","volume":"97","author":"L Hou","year":"2024","unstructured":"Hou L, Ying Y, Wu W, et al. The effect of GnRHa treatment on BMI in central precocious puberty: a systematic review and meta-analysis. Horm Res Paediatr. 2024;97(5):419\u201332.","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"2991_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1515\/jpem-2023-0416","volume":"37","author":"X Zhu","year":"2024","unstructured":"Zhu X, Qin J, Xue W, et al. The effect of GnRH analog treatment on BMI in children treated for precocious puberty: a systematic review and meta-analysis. J Pediatr Endocrinol Metab. 2024;37(4):297\u2013308.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"7","key":"2991_CR25","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/apa.17185","volume":"113","author":"CS Uldbjerg","year":"2024","unstructured":"Uldbjerg CS, Lim YH, Renault CH, et al. Girls with idiopathic central precocious puberty did not display substatial changes in body mass index after treatment with gonadotropin-releasing hormone analogues. Acta Paediatr. 2024;113(7):1602\u201311.","journal-title":"Acta Paediatr"},{"issue":"10","key":"2991_CR26","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1007\/s12325-022-02264-5","volume":"39","author":"X Li","year":"2022","unstructured":"Li X, Li H, Shi H, et al. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: a phase\u00a03 randomized controlled trial. Adv Ther. 2022;39(10):4663\u201377.","journal-title":"Adv Ther"},{"issue":"22","key":"2991_CR27","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1056\/NEJMcp0800459","volume":"358","author":"JC Carel","year":"2008","unstructured":"Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22):2366\u201377.","journal-title":"N Engl J Med"},{"key":"2991_CR28","unstructured":"Ipsen Limited. Summary of product characteristics, Decapeptyl SR 11.25mg (triptorelin pamoate). European Medicines Agency, 2022. https:\/\/www.medicines.org.uk\/emc\/product\/780\/smpc. Accessed September 2022."},{"key":"2991_CR29","first-page":"208","volume":"26","author":"PHC Cornford","year":"2023","unstructured":"Cornford PHC, Sassman J, Frankcom I, Braybrook S. Increased use of 6-monthly gonadotrophin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England. J MedEcon. 2023;26:208\u201318.","journal-title":"J MedEcon"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02991-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02991-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02991-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T08:12:06Z","timestamp":1731139926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02991-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02991-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xiao Yu, Xinran Cheng, Haiyan Wei, Xu Xu, Chunxiu Gong, Guimei Li, Hui Yao, Li Zhou, Yan Zhong, Yu Yang, Feihong Luo, and Yining Zhang have no competing interests to disclose. Frank Huang, Xiaofeng Shi, and Patrick Cabri are employees of Ipsen. Xiaoping Luo has no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted under the provisions of the Declaration of Helsinki, in accordance with International Conference on Harmonization (ICH), Consolidated Guideline on Good Clinical Practice (GCP) and in compliance with independent ethics committee and informed consent regulations. The study protocol, amendments, and informed consent form and updates were reviewed and approved by an ethics committee prior to commencement of the study, and during the study where applicable. Written informed consent was acquired from one or both of each participant\u2019s parents or guardians, and signed approval was obtained from the child when applicable, prior to study entry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}